idasanutlin
Small moleculeexperimental
Clinical trial activity
19 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
16
Phase 2
12
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01462175)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Chromosome Aberrations · Phase 1/Phase 2
- Glioblastoma · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 3
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Neoplasms · Phase 2
- Neuroblastoma · Phase 1/Phase 2
- Polycythemia Vera · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Rhabdoid Tumor · Phase 1
- Thrombocythemia, Essential · Phase 1
Mechanism of action
- p53-binding protein Mdm-2INHIBITOR
MDM2 inhibitor
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F- Mol. weight
- 616.49 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2402737 ↗
Also known as
- idasanutlin
- idasanutlin
- idasanutlin
- idasanutlin
- idasanutlin (rg-7388)
- rg7388
- rg7388
- rg-7388
- rg-7388
- ro5503781
- ro5503781
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05952687 | Phase 1 | Jan 31, 2024 | St. Jude Children's Hospital |
| NCT04589845 | Phase 2 | Nov 30, 2020 | Roche |
| NCT04029688 | Phase 1/Phase 2 (Phase 2) | Oct 26, 2019 | Roche |
| NCT03850535 | Phase 1/Phase 2 (Phase 2) | Mar 25, 2019 | Roche |
| NCT03566485 | Phase 1/Phase 2 (Phase 2) | Jun 25, 2018 | Genentech, Stand Up To Cancer, Vanderbilt University |
| NCT03287245 | Phase 2 | Feb 21, 2018 | Roche |
| NCT03337698 | Phase 1/Phase 2 (Phase 2) | Dec 27, 2017 | Roche |
| NCT03362723 | Phase 1 | Nov 27, 2017 | Roche |
| NCT03158389 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2017 | Deutsche Krebshilfe e.V., German Cancer Research Center, University of Heidelberg |
| NCT03135262 | Phase 1/Phase 2 (Phase 2) | Jun 15, 2017 | Roche |
| NCT02828930 | Phase 1 | Sep 8, 2016 | Roche |
| NCT02670044 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2016 | Roche |
| NCT02545283 | Phase 3 | Dec 30, 2015 | Roche |
| NCT02624986 | Phase 1/Phase 2 (Phase 2) | Dec 23, 2015 | Roche |
| NCT02633059 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2015 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT02407080 | Phase 1 | Apr 1, 2015 | Icahn School of Medicine at Mount Sinai, Roche, The Leukemia and Lymphoma Society |
| NCT01901172 | Phase 1 | Aug 1, 2013 | Roche |
| NCT01773408 | Phase 1 | Feb 1, 2013 | Roche |
| NCT01462175 | Phase 1 | Nov 1, 2011 | Roche |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 15 | 14 | 3 | 2011 |
| Deutsche Krebshilfe e.V. | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Genentech | For profit | 1 | 0 | 1 | 2018 |
| German Cancer Research Center | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
| Stand Up To Cancer | Academic/Hospital | 1 | 0 | 1 | 2018 |
| St. Jude Children's Hospital | Academic/Hospital | 1 | 1 | 1 | 2024 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Heidelberg | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2018 |
12 organizations
Page 1 / 1